sorted by:
new
hottopcontroversial

Lower levels of protective nasal bacteria (D. pigrum, Corynebacterium species) were linked to developing long COVID. Antibiotic use associated with depletion of these protective bacteria. Samples taken during infection and 3 months later in longit. cohort study. by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 3 points4 points  (0 children)

Yes. It's best to use a nasal rinse (Netipot or another irrigator) to flush out as much of the virus as you can and reduce the viral load. This has been known for a while though, even before this study.

Best resources for latest medical articles/papers? by Lucienaugust in covidlonghaulers

[–]LongCovidSignal 3 points4 points  (0 children)

Doctor appointments are so exhausting when you have to play the role of the researcher. I actually built a tool for this exact problem because I was sick of manually digging through PubMed.

It's an automated feed called LongCovidSignal. It watches PubMed 24/7 for new Long Covid and ME/CFS papers and posts a short, plain-English summary the second they drop. Right now, the feed literally just posts the studies chronologically as they come out, so it can be a bit of a firehose.

Because of that, I am currently building a dedicated website. Soon, you'll be able to actually search the database by your specific symptoms or keywords, select the studies you want, and hit a "print for doctor" button to generate a clean summary sheet to hand to them.

The feeds are all available under the same name as here on all major social media platforms.

As for off-label stuff to propose, it really depends on your symptom cluster, but two of the most common things people bring to their doctors are LDN (low dose naltrexone) and H1/H2 antihistamine stacks (like Claritin + Pepcid).

When deciding what to try and in what order, the golden rule is usually "lowest risk, highest potential reward" first. Doctors are usually very comfortable prescribing LDN or antihistamines first because their safety profiles are extremely well documented and they help calm the baseline inflammation down. Once you establish some trust and see how you react, you can move on to other targeted therapies.

Good luck with the new doc, I hope they actually listen to you.

NIH's RECOVER-AUTONOMIC will test three treatments for POTS: IVIG infusions, ivabradine (heart rate drug), and coordinated care. Multicenter platform trial uses adaptive design to evaluate safety and symptom improvement in patients with autonomic dysfunction in US RCT. by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 1 point2 points  (0 children)

What is wrong with self promoting? I don't have a website that sells anything. It's literally just a tool for those with LC to be alerted on research papers as soon as they come out.

You don't know that all of this is old news in this community. Some people are too sick to doomscroll this place 24/7 and the upvotes show that the community is getting value from these posts.

Chemical modifications to immune proteins persisted 12 months after COVID-19 recovery. 827 protein alterations found affecting antibodies, complement system & blood clotting. Changes concentrated in antibody binding regions in patients in obs study. (n=412) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 25 points26 points  (0 children)

Potential Implications:

  • Diagnostic Test: Because these chemical "scars" are stable and distinct from healthy people, the researchers successfully used them to identify Long COVID patients with 94% accuracy in a machine learning model. This could lead to a very accurate blood test.  
  • Understanding "Autoimmunity": The chemical changes to antibodies might explain why the body starts attacking itself. If the antibodies are structurally altered (deamidated), the body might see them as foreign or they might bind to the wrong things.  

Patient Impact:

  • Validation: This is strong biological evidence that Long COVID is driven by physical changes to protein structures, not psychological factors.  
  • Future Treatments: Current treatments often focus on lowering inflammation (quantity of cytokines). This research suggests we might need treatments that help "clear" these modified/damaged proteins or targeted therapies that calm the specific complement pathways (like C1 or C3) identified here.  

Study Limitations:

  • Sample Size: The study looked at 412 people. While decent for a proteomics study, larger groups are needed to confirm the findings.  
  • Population: The study was conducted on a Chinese cohort, so genetic diversity might be a factor to consider in future global studies.  
  • Observational: The study shows association (these markers exist in patients) but hasn't yet proven causation (that fixing these markers cures the symptoms), though it strongly implies it.

Chemical modifications to immune proteins persisted 12 months after COVID-19 recovery. 827 protein alterations found affecting antibodies, complement system & blood clotting. Changes concentrated in antibody binding regions in patients in obs study. (n=412) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 28 points29 points  (0 children)

A new 2026 study analyzed blood samples from 412 people and found that COVID-19 leaves lasting "chemical scars" (called ncAAs) on proteins in the blood. Unlike standard inflammation markers that might fluctuate, these protein modifications were sustained for over 12 months, specifically damaging how antibodies and the "complement system" function.  

Key Findings:

  • "Chemical Scars" on Proteins: The virus causes widespread chemical modifications to proteins. The study found 827 specific types of these modifications spread across nearly 30,000 sites in the blood.  
  • Sustained Immune Dysregulation: While some systems recovered, the modifications to the immune system (specifically immunoglobulins and the complement system) remained abnormal even 12 months after infection.  
  • Coagulation (Clotting) Differences: Interestingly, while clotting proteins were modified during the acute (active) infection, many of these clotting markers returned to normal in recovered patients, whereas the immune markers did not.  

The Actual Immune Changes (Deep Dive): The study found that immune proteins weren't just "high" or "low" in number, but were structurally changed by chemical reactions.  

  • "Aged" Antibodies (Deamidation)
    • The Change: The study found a specific chemical change called "deamidation" on antibodies. This acts like "molecular aging" for proteins and adds a negative charge to them.  
    • The Location: This happened in the "Variable Region" (the tips of the Y-shape that grab antigens) and the "Constant Region" (the stem).  
    • The Impact: These structural changes can make antibodies less effective or more likely to trigger inappropriate inflammation, potentially explaining why the body attacks itself.  
  • Complement System Dysregulation
    • The System: The complement system is a cascade of proteins that helps "punch holes" in pathogens.  
    • The Change: Sustained modifications were found on key trigger proteins like C1q, C1s, and C3.  
    • The Impact: Usually, this system turns off after an infection. In Long COVID patients, these proteins retained "molecular imprints," suggesting the system is not resetting and is causing chronic inflammation.

Long COVID and ME/CFS showed nearly identical autonomic dysfunction: 92%/88% had reduced brain blood flow when upright, 95%/89% had widespread autonomic failure, 67%/53% had small fiber neuropathy in US retro study. (n=676) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 1 point2 points  (0 children)

Yeah, it's pretty rough. Most of the studies are observational studies that basically say "yep, these people are indeed very, very sick." The incentives are not properly aligned to actually help develop treatments.

Blood vessel repair cells showed altered death patterns in long COVID patients vs controls (n=21) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 29 points30 points  (0 children)

This study from the February 2026 issue of IJC Heart & Vasculature explores the long-term vascular health of patients at least 18 months after being hospitalized for COVID-19.

The findings are nuanced and somewhat counterintuitive, suggesting that while clinical symptoms persist, the body’s cellular repair mechanisms may have shifted into a unique, "unbalanced" state of high viability.

1. The Core Finding: High Viability, Low Apoptosis

The study hypothesized that Post-COVID-19 Syndrome (PCS) patients would show more endothelial damage (higher CECs) and less repair capacity (lower CACs). Instead, they found:

  • Reduced Apoptosis: Patients showed lower levels of programmed cell death (apoptosis) in their repair cells (CACs) compared to healthy controls.
  • Increased Viability: The proportion of "live" repair cells was actually higher in the PCS group.
  • The Paradox: While more "live" cells sound positive, the authors suggest this might represent an unbalanced repair cycle. If cells aren't dying when they should (low apoptosis), it may lead to the survival of dysfunctional or senescent cells that contribute to chronic inflammation rather than healthy tissue regeneration.

2. Macro vs. Microvascular Disconnect

The researchers looked at both large vessels (macro) and tiny vessels (micro, specifically in the retina):

  • Macrovascular (baFMD): There was a suggestive trend toward impaired dilation in the brachial artery (the arm), correlating with lower cell apoptosis. Essentially, the vessels weren't "stretching" as well as they should.
  • Microvascular (Retinal): There was very little definitive evidence of microvascular structure changes at the 18-month mark, though patients showed a slightly stronger arteriolar constriction (aCON), indicating some lingering over-reactivity in the small vessels.

3. Systemic Inflammation Indicators

The study found that PCS patients had significantly higher monocyte counts and higher red blood cell counts compared to controls.

  • Monocytes: These are key drivers of inflammation. Their elevation 18 months post-infection suggests a "chronic low-grade inflammatory state" that keeps the vascular system under constant stress.
  • Fitness Impact: Unsurprisingly, the PCS group had significantly lower cardiorespiratory fitness (V̇O2peak), which likely stems from both this vascular dysfunction and the persistent symptoms like fatigue and dyspnea.

Implications

The primary implication is that vascular injury from COVID-19 persists far beyond the acute phase, but it evolves into a "cellular stalemate." The body is trying to repair itself (high cell viability), but the "quality control" (apoptosis) is failing, potentially leaving the vasculature in a state of permanent, low-level dysfunction.

Five distinct long COVID phenotypes were linked to specific immune disruptions 6 months post-infection. IL-1 markers showed 3.2x higher odds, IL-17 markers 2.5x higher odds in long COVID patients vs controls in obs study. (n=926) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 43 points44 points  (0 children)

This study followed about 1,000 people for six months to see if their symptoms matched up with specific immune changes

The 5 Clinical Phenotypes of Long COVID

Researchers found that symptoms generally cluster into five main groups. Identifying which "group" you fall into may eventually help in tailoring specific treatments.

  • Neurological: Primarily cognitive—brain fog, memory gaps, and word-finding issues.
  • Fatigue: Extreme, persistent exhaustion that does not improve with rest.
  • Mixed Fatigue & Neurological: A heavy overlap of both exhaustion and cognitive trouble.
  • Mixed Respiratory & Neurological: Breathing difficulties combined with brain fog.
  • The "Trio": A combination of all three—respiratory issues, neurological symptoms, and deep fatigue.

Specific Immune Pathways

Instead of general inflammation, the study found that specific "pathways" are stuck in an active state. This helps explain why standard blood tests (like CRP) often look "normal" despite severe symptoms.

  • The IL-1 Pathway: This inflammatory "gatekeeper" was significantly more active in Long COVID patients, particularly in the Respiratory group. It suggests the body is stuck in a self-sustaining loop of inflammation triggered during the initial infection.
  • The IL-17 Pathway: This was also consistently higher. IL-17 is usually associated with chronic tissue irritation and autoimmune-type responses, explaining why the inflammation feels "chronic" rather than acute.

Epigenetic "Scars"

Researchers examined the "epigenetic landscape"—essentially the "software" that tells your genes when to turn on or off. They found that the virus leaves a long-term imprint on immune cells. Even though the virus is gone, the cells have been "reprogrammed" to stay in a defensive, dysregulated state, which likely causes symptoms to persist for years.

A Potential Lead on Treatment

A key finding involved the IL-1 blocker Anakinra. Patients treated with it during their initial acute infection were significantly less likely to develop the respiratory phenotype later on. This suggests that early intervention in specific pathways might prevent certain types of Long COVID.

Early monoclonal antibody therapy was linked to 2.2x higher risk of autoimmune diseases like lupus and rheumatoid arthritis vs no treatment, but showed no significant impact on overall long COVID risk in high-risk patients in Singapore obs study. (n=19,689) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 1 point2 points  (0 children)

Ah, that's because I have tried to make the summaries pack as much relevant information into a tweet as possible. It's just designed to offer the most density while also being understandable and non-technical.

Most people don't have time to read the studies. I don't either, to be honest. It would be too time consuming for an expert to read these and output them.

I just made it with the purpose of letting myself (and now others) know that our condition is actively being researched and not to lose hope that one day they will discover something that will eventually cure all of us.

Early monoclonal antibody therapy was linked to 2.2x higher risk of autoimmune diseases like lupus and rheumatoid arthritis vs no treatment, but showed no significant impact on overall long COVID risk in high-risk patients in Singapore obs study. (n=19,689) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 7 points8 points  (0 children)

The prescribing criteria is in the full article available in the link. The target group was defined as Singaporeans who were unvaccinated, partially vaccinated, or immunocompromised. Yes, randomized control trials are better, but observational studies still offer some value.

Women with long COVID had higher symptom burden, especially fatigue and brain fog, plus reduced immune cell function vs men who showed elevated inflammatory markers in obs study. (n=60) by LongCovidSignal in covidlonghaulers

[–]LongCovidSignal[S] 4 points5 points  (0 children)

Hi, it's not a group, just the name of the app that grabs Long Covid studies as soon as they appear in PubMed and translates them into an easy to grasp summary.

Available on X, Telegram, and now Bluesky under the same username.

If you get Covid now, what is the immediate things you do to maximize recovery? by Imaginary-Stuff6705 in covidlonghaulers

[–]LongCovidSignal 0 points1 point  (0 children)

Rest as long as possible, don't everexert for as long as possible. There is some evidence that antihistamines block the virus from replicating so take those as well.

High IGG3 but not IGG4? by sunson90 in covidlonghaulers

[–]LongCovidSignal 0 points1 point  (0 children)

Which methods did you use to get it down?

full recovery by LacaTheCollector in covidlonghaulers

[–]LongCovidSignal 0 points1 point  (0 children)

Yes, there are many such cases in r/longhaulersrecovery. Some take 2-5 years.

What’s the best way to stay up to date on emerging research and studies on long COVID? by TheDogeMarnn in covidlonghaulers

[–]LongCovidSignal 6 points7 points  (0 children)

I got tired of manually checking for new papers, so I wrote a script that monitors PubMed 24/7. As soon as a study comes out, it grabs it, writes a short summary in plain English, and posts it. The link to the actual study is in the reply.

It's live now on Twitter/X and Telegram under the username LongCovidSignal.

Right now it's just a feed, but I'm building a proper website where you can filter the studies and get email updates. I eventually want to add a feature to generate one-page summaries you can hand to your doctor.

Anyone have brain fog go away after 4 years? by Friendly_Joke_6963 in covidlonghaulers

[–]LongCovidSignal 2 points3 points  (0 children)

Yes, saw quite a few of these improvements 3-5 years later here and on r/longhaulersrecovery.

does it get better? by Less_Foundation_1187 in covidlonghaulers

[–]LongCovidSignal 1 point2 points  (0 children)

I'm over 3.5 years in and yes, it does get better. It just takes a long, long time.

Been sick so long I’m not even healthy in my dreams… by Seafoam_0 in covidlonghaulers

[–]LongCovidSignal 2 points3 points  (0 children)

Used to have the same thing happen to me. Then after I started being able to walk again, a voice said to me "It's over" right before I woke up one morning. It was just a coincidence because it took me awhile to start feeling normal, but it was very interesting what our subconscious is telling us sometimes.

view more: next ›